City of Hope investigators have formulated an innovative plug-and-play technique that incorporates engineered molecules into chimeric antigen receptor (CAR) T cells post-treatment, based on findings shared this month in Cancer Immunology Research, an American Association for Cancer Research journal. The preclinical study offers a flexible approach to help CAR T cells keep pace with mutating tumors by allowing scientists to better control the cells and redirect them to attack different types of cancer.
Overcoming CAR T Limitations in Solid Tumors
CAR T cell therapy genetically reprograms a patient’s immune cells to seek out and kill cancer, revolutionizing treatment for blood cancers. Present-day treatments remain mostly fixed in their design, lacking the capacity to adjust once the modified cells enter a patient’s circulatory system.
According to John Williams, Ph.D., co-senior author, tumors adapt to CAR T therapies, leading to treatment failure and cancer relapse. “To remain effective, our therapies need to adapt, too,” Williams said. “City of Hope has created a system that allows us to reconfigure these potent cancer killers as the tumor progresses.”
Did You Know? City of Hope treats about 90% of CAR T patients in an outpatient setting and has had more than 2,000 patients participate in its immune effector and CAR T cell trials, making it home to one of the nation’s largest cellular and outpatient CAR T programs.
The Science Behind meCAR T Technology
To overcome hurdles such as short lifespans, potential serious side effects, and an inability to alter cells after infusion, Christine Brown, Ph.D., deputy director of T Cell Therapeutics Research Laboratories at City of Hope and co-senior author, teamed up with Dr. Williams. They built upon earlier research involving a molecular docking system called meditope, which adds new capabilities to immunotherapies.
In the new study, researchers redesigned CAR T cells to connect with a small molecule called meP, establishing a new cell type known as meCAR T. The team subsequently demonstrated that meCAR T cells could be equipped with different add-ons to help them track, grow, and recognize a wider range of cancer cells.
Delivering Software-Like Updates to Living Cells
“Much like a software update adds new features to a smartphone after you buy it, meditope allows us to send new instructions to CAR T cells already in the body,” said Dr. Williams, who serves as a professor in the Department of Cancer Biology and Molecular Medicine at the Beckman Research Institute of City of Hope.
The team programmed meCAR T cells to perform new functions that give researchers better control over how the cells locate and attack cancer. According to Dr. Brown, City of Hope’s Heritage Provider Network Professor in Immunotherapy, the platform’s primary strength is its flexibility.
“Instead of hardwiring every function into a CAR T cell, we can use protein-adaptor plug-ins to add new capabilities as needed,” Dr. Brown said, noting this improves the cells’ ability to overcome tumor heterogeneity and barriers limiting CAR T therapy in solid tumors.
Next Steps for Clinical Testing
The research team plans to translate these preclinical findings into clinical testing. Two Phase I clinical trials are currently being prepared by scientists at City of Hope to assess the safety and functionality of meCAR T cells as a therapeutic framework for individuals suffering from solid tumors and acute myeloid leukemia.
“We’re excited about this new platform that allows us to control CAR T cells,” Dr. Brown said. “Our approach potentially could be applied across many different cancers and other diseases for which CAR T cell therapies are being developed.”
Frequently Asked Questions
What is meCAR T technology?
meCAR T is a new type of engineered cell developed by City of Hope researchers that connects with a small molecule called meP, allowing scientists to add engineered molecules to CAR T cells after treatment using protein-adaptor plug-ins.
Why do traditional CAR T therapies fail against some tumors?
Traditional CAR T therapies are hardwired before infusion and cannot adapt after being introduced to the patient’s bloodstream, allowing evolving tumors to escape immune attacks and drive relapse, according to City of Hope researchers.
What are the next clinical research steps for meCAR T cells?
A pair of Phase I clinical trials are currently being set up by investigators to test how safe and active meCAR T cells are when administered to patients diagnosed with solid tumors and acute myeloid leukemia.
Join the Conversation: What are your thoughts on the future of adaptable cell therapies in oncology? Share your perspective in the comments below, or subscribe to our newsletter for more updates on breakthrough medical research.
Worth a look